C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals
China’s powerhouse private equity player C-Bridge Capital is dishing out $35 million to experiment with a new partnership model.
Its partners at Nuance Biotech announced a deal with Pacira Pharma that gave them development and commercialization rights of Exparel in China. What went unmentioned at the time was the role C-Bridge played, identifying the opportunity and facilitating the pact.
That deal makes sense, says Nuance CEO Mark Lotter, because the non-opioid pain drug fits right with their focus in the surgical space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.